Overview

Pneumococcal Conjugate Vaccine in Aging Renal Transplant

Status:
Terminated
Trial end date:
2020-02-28
Target enrollment:
Participant gender:
Summary
The goal of the research proposed in the current application is to first define how much antibody aging renal transplant and dialysis recipients make after they are vaccinated with the pneumonia vaccine and how this compares to similar aged persons with good renal function and healthy young adults. The investigators will study differences in the kind of B cells and markers on the B cells that are known to be important in the response to the pneumonia vaccine in aging renal transplant and aging dialysis recipients compared to similarly aged and young healthy controls. Finally, the investigators will study how safe the pneumonia vaccine is in aging renal transplants. The answers to these questions will help in designing a better vaccine for older people with a renal transplant or on dialysis.
Phase:
Early Phase 1
Details
Lead Sponsor:
VA Office of Research and Development
Treatments:
Heptavalent Pneumococcal Conjugate Vaccine
Vaccines